Skip to content

Clinical trials

Phase 3 Hyperlipidemias trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperlipidemias Phase: Phase 3 Country / region: China Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20111
20131
20161
20201
20214
20222
20233
20242
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Recruiting5
Active, not recruiting2
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals5
Akeso3
Shanghai Junshi Bioscience Co., Ltd.2
Shenzhen Salubris Pharmaceuticals Co., Ltd.2
Amgen1
Beijing Suncadia Pharmaceuticals Co., Ltd1
Gan & Lee Pharmaceuticals.1
Kowa Company, Ltd.1
Otsuka Beijing Research Institute1
Pfizer1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperlipidemias19
Hypercholesterolemia5
Cardiovascular Diseases4
Dyslipidemias4
Aortic Valve Stenosis2
Heart Failure2
Hyperlipoproteinemia Type II2
Myocardial Infarction2
Stroke2
Acute Coronary Syndrome1

Trials

Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.